Savella Withdrawal & Tapering Guide
milnacipran
Boxed Warning
Suicidality risk in children, adolescents, and young adults under 25 during initial treatment.
In short
Savella (milnacipran) is an SNRI with a half-life of 6–8 hours. SNRI approved for fibromyalgia (not depression in the US). It is also sold as Ixel.
- Class
- SNRI
- Half-life
- 6–8 hours
- Common doses
- 12.5mg, 25mg, 50mg, 100mg
Educational reference only. Dose changes are decided with the prescriber who knows your history.
Overview
Milnacipran is a serotonin-norepinephrine reuptake inhibitor (SNRI) approved in the US for fibromyalgia management. It has a roughly 3:1 selectivity for norepinephrine over serotonin reuptake inhibition.
12.5mg, 25mg, 50mg, 100mg
Tablets: 12.5mg, 25mg, 50mg, 100mg; Titration pack: 12.5mg and 25mg tablets
Category C (risk cannot be ruled out)
Mechanism of Action
Dual reuptake inhibitor of serotonin and norepinephrine with preferential activity at the norepinephrine transporter (NET > SERT, approximately 3:1 ratio).
Taper Notes
SNRI approved for fibromyalgia (not depression in the US). Short half-life requires twice-daily dosing. Taper gradually — abrupt discontinuation causes withdrawal syndrome.
Hyperbolic Tapering Guidance
Reduce dose gradually over at least 1–2 weeks. Consider smaller dose reductions at lower doses. Short half-life means symptoms can emerge within 24 hours of missed dose.
Summary written by TaperCommunity, informed by the Maudsley Deprescribing Guidelines (Horowitz & Taylor) and related literature — see Sources & References below. Not affiliated with or endorsed by the Maudsley.
Common Withdrawal Symptoms
Interactions & Safety
Drug Interactions
- MAOIs — contraindicated (risk of serotonin syndrome)
- Serotonergic drugs increase serotonin syndrome risk
- Epinephrine and norepinephrine — enhanced pressor effects
Food Interactions
- Food does not significantly affect overall absorption (AUC unchanged)
- No specific food contraindications
Contraindications
- MAOIs within 14 days
- Uncontrolled narrow-angle glaucoma
- Known hypersensitivity to milnacipran
Toxicity
Serotonin syndrome risk. Hypertension and tachycardia. Hepatotoxicity reported rarely.
Pharmacokinetics
ADME Profile
Well absorbed (85–90% bioavailability). Tmax ~2–4 hours. Food does not affect AUC but delays Tmax.
~400 L
Hepatic — primarily conjugation (glucuronidation), not significantly CYP-mediated. Active desethyl metabolite.
Renal (55% unchanged, 24% as glucuronide conjugate).
13%
~60 L/hr
Need a clinician who understands tapering?
Browse our map of deprescribing-informed providers worldwide.
Other Drug Profiles
The arithmetic of a proportional reduction
The Maudsley Deprescribing Guidelines and NICE NG222 describe reducing SNRI medications by a proportion of the previous dose rather than by a fixed amount, so each cut is smaller than the last. The table shows what that arithmetic produces at 10% per step, using 25 mg only as a worked example. How large each step is, how long it is held, and whether this pattern applies at all are decisions for the person and their prescriber.
| Step | % of starting dose | Worked example (25 mg start) |
|---|---|---|
| Start | 100% | 25 mg |
| Step 1 | 90% | 22.5 mg |
| Step 2 | 81% | 20.3 mg |
| Step 3 | 73% | 18.2 mg |
| Step 4 | 66% | 16.4 mg |
| Step 5 | 59% | 14.8 mg |
| Step 6 | 53% | 13.3 mg |
| Step 7 | 48% | 12 mg |
| Step 8 | 43% | 10.8 mg |
This is an illustration of a published method, not a schedule for anyone. It does not account for how long you have taken Savella, your current dose, formulation, or history. TaperCommunity does not recommend doses or dose changes; those are agreed with your prescriber.
Frequently asked questions about Savella
What are the withdrawal symptoms of Savella (milnacipran)?
Common withdrawal symptoms of Savella (milnacipran) include: headache, nausea, dizziness, irritability, insomnia, paresthesia, anxiety. Symptom severity varies by individual, dose, and duration of use.
How should I taper off Savella (milnacipran)?
SNRI approved for fibromyalgia (not depression in the US). Short half-life requires twice-daily dosing. Taper gradually — abrupt discontinuation causes withdrawal syndrome. Reduce dose gradually over at least 1–2 weeks. Consider smaller dose reductions at lower doses. Short half-life means symptoms can emerge within 24 hours of missed dose.
Can I stop Savella cold turkey?
Stopping Savella abruptly is not recommended. Its half-life is 6–8 hours, and the receptor adaptations built up during treatment do not reverse at that speed, so a sudden stop tends to produce the sharpest withdrawal. Prescribing guidance favours gradual, proportional reductions agreed with your prescriber.
How long does Savella stay in your system?
Savella (milnacipran) has a half-life of 6–8 hours. A drug is mostly cleared after about five half-lives, so Savella is largely out of the body roughly 30 to 40 hours after the last dose, longer in older adults or with liver or kidney impairment. Withdrawal symptoms often begin before the drug has fully cleared and continue after it has, because the adaptations the brain made during treatment reverse more slowly than the drug leaves the blood.
Sources & References
Savella (milnacipran) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.
Encyclopedic & chemical databases
Neutral, high-authority entity references.
Peer-reviewed research
Primary literature cited in this taper guide.
- Horowitz MA, Taylor D 2019 — Tapering of SSRI treatment to mitigate withdrawal symptoms (hyperbolic taper) (The Lancet Psychiatry)
- Davies J, Read J 2019 — A systematic review into the incidence, severity and duration of antidepressant withdrawal effects (Addictive Behaviors)
- Framer A 2021 — The patient voice: an exploration of the experience of withdrawal from antidepressants (Therapeutic Advances in Psychopharmacology)
Clinical guidelines
Evidence-based deprescribing and prescribing standards.
Deprescribing-specific resources
Clinician-facing references on tapering protocols.
- Deprescribing.org — Evidence-based deprescribing algorithms from the Bruyère Research Institute
- Royal College of Psychiatrists — Stopping antidepressants — UK clinical guidance on safely discontinuing antidepressants
Patient-advocacy & lived-experience
Long-running communities documenting withdrawal experience.
- Surviving Antidepressants — tapering forum — Long-running community archive of antidepressant taper experiences
- Inner Compass Initiative — Withdrawal Project — Peer-led resources for psychiatric drug withdrawal
- Mad in America — antidepressant withdrawal archive — Journalism and personal narratives on SSRI/SNRI discontinuation
- RxISK — adverse drug reaction reporting — Independent database of patient-reported adverse effects
TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.